Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis

Sibel Ali,Ana Ion,Olguța Anca Orzan,Beatrice Bălăceanu-Gurău
DOI: https://doi.org/10.3390/pharmaceutics16111425
IF: 6.525
2024-11-08
Pharmaceutics
Abstract:Atopic dermatitis is one of the most common inflammatory skin diseases, with an increasing incidence among both children and adults. The recurrent nature, often with the persistence of symptoms, and the polymorphism of the response to current therapies have led to increased research in the therapeutic area dedicated to this condition. The understanding of pathophysiological pathways has contributed to the development of innovative therapies, including biological therapies, JAK inhibitors, but also emerging technologies like nanotechnology-based drug delivery systems. These innovations promise enhanced efficacy, reduced side effects, and improved patient outcomes. The ongoing exploration of novel vehicles, formulations, and natural biopolymers, along with cutting-edge therapeutic agents like tapinarof and mesenchymal stem cells, highlights the potential for an even more precise and personalized management of AD in the future. Despite these advances, challenges persist, particularly in ensuring the long-term safety, accessibility, and broader application of these therapies, necessitating continued research and development.
pharmacology & pharmacy
What problem does this paper attempt to address?